Valvular & structural heart disease
Transcatheter Edge-to-Edge Repair in COAPT-Ineligible Patients With Functional Mitral Regurgitation
Main finding · Death or HFHResult — go to the resultHazard ratio 1.73 95% CI 1.57–1.91Authors' conclusion
Among patients who underwent MTEER for FMR in the TVT Registry, nearly one-half would have been ineligible for the COAPT trial. Health status improvement at 30 days was similar in COAPT-ineligible and COAPT-eligible patients, but trial-ineligible patients had higher 1-year rates of death or HFH.
Study context
- Population
- Patients undergoing mitral valve transcatheter edge-to-edge repair (MTEER) for functional mitral regurgitation, TVT Registry, 2013–2020
- Participants
- 6,675 patients
- Exposure
- COAPT-ineligible vs COAPT-eligible patients undergoing MTEER
- Trial-ineligiblen = 2,954
- Trial-eligiblen = 3,721reference
- Outcome
- Death or HF hospitalization (heart failure hospitalization (HFH))
- Follow-up
- 1 year
Methodological detailsmultivariable models
- Multivariable models
Main finding
Death or HFH
Hazard ratio
1.73
95% CI 1.57–1.91
P < 0.001
Trial-ineligible vs Trial-eligible
HR 1.73 (95% CI 1.57–1.91); P < 0.001
As reported in the abstract
Observational data: associations, not effects.
Further findings
Technical procedural success
Clinically meaningful improvement in health status · 30 days
- Technical procedural success: P < 0.001
Safety
In-hospital complications
- In-hospital complications: P < 0.001
Original publication
Transcatheter Edge-to-Edge Repair in COAPT-Ineligible Patients With Functional Mitral Regurgitation. J Am Coll Cardiol. Published 30 January 2024. doi:10.
Summarised from the published abstract; every number is checked against it